全文获取类型
收费全文 | 1922195篇 |
免费 | 136763篇 |
国内免费 | 16125篇 |
专业分类
耳鼻咽喉 | 23951篇 |
儿科学 | 58867篇 |
妇产科学 | 48691篇 |
基础医学 | 288519篇 |
口腔科学 | 49141篇 |
临床医学 | 190183篇 |
内科学 | 355534篇 |
皮肤病学 | 37903篇 |
神经病学 | 147129篇 |
特种医学 | 70141篇 |
外国民族医学 | 515篇 |
外科学 | 263836篇 |
综合类 | 64330篇 |
现状与发展 | 42篇 |
一般理论 | 572篇 |
预防医学 | 156601篇 |
眼科学 | 43415篇 |
药学 | 149259篇 |
196篇 | |
中国医学 | 14858篇 |
肿瘤学 | 111400篇 |
出版年
2021年 | 23465篇 |
2020年 | 15858篇 |
2019年 | 20604篇 |
2018年 | 26825篇 |
2017年 | 21189篇 |
2016年 | 22372篇 |
2015年 | 27656篇 |
2014年 | 36510篇 |
2013年 | 49657篇 |
2012年 | 69810篇 |
2011年 | 74968篇 |
2010年 | 44411篇 |
2009年 | 39059篇 |
2008年 | 64495篇 |
2007年 | 67714篇 |
2006年 | 67063篇 |
2005年 | 64668篇 |
2004年 | 59329篇 |
2003年 | 56305篇 |
2002年 | 53874篇 |
2001年 | 80261篇 |
2000年 | 82454篇 |
1999年 | 69678篇 |
1998年 | 20829篇 |
1997年 | 18848篇 |
1996年 | 18170篇 |
1995年 | 17333篇 |
1994年 | 15936篇 |
1992年 | 53543篇 |
1991年 | 53590篇 |
1990年 | 52256篇 |
1989年 | 49969篇 |
1988年 | 46100篇 |
1987年 | 45128篇 |
1986年 | 42679篇 |
1985年 | 40740篇 |
1984年 | 30493篇 |
1983年 | 25958篇 |
1982年 | 15083篇 |
1979年 | 27997篇 |
1978年 | 19912篇 |
1977年 | 16209篇 |
1976年 | 16272篇 |
1975年 | 17489篇 |
1974年 | 20928篇 |
1973年 | 20259篇 |
1972年 | 18758篇 |
1971年 | 17694篇 |
1970年 | 16393篇 |
1969年 | 14975篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
33.
Annals of Nuclear Medicine - The Response Evaluation Criteria In Solid Tumors (RECIST) is the most used radiological method for evaluating response after peptide receptor radionuclide therapy... 相似文献
34.
35.
36.
Xiaoyan Lu Isabelle R. Miousse Sandra V. Pirela Jodene K. Moore Stepan Melnyk 《Nanotoxicology》2016,10(5):629-639
Evidence continues to grow on potential environmental health hazards associated with engineered nanomaterials (ENMs). While the geno- and cytotoxic effects of ENMs have been investigated, their potential to target the epigenome remains largely unknown. The aim of this study is two-fold: 1) determining whether or not industry relevant ENMs can affect the epigenome in vivo and 2) validating a recently developed in vitro epigenetic screening platform for inhaled ENMs. Laser printer-emitted engineered nanoparticles (PEPs) released from nano-enabled toners during consumer use and copper oxide (CuO) were chosen since these particles induced significant epigenetic changes in a recent in vitro companion study. In this study, the epigenetic alterations in lung tissue, alveolar macrophages and peripheral blood from intratracheally instilled mice were evaluated. The methylation of global DNA and transposable elements (TEs), the expression of the DNA methylation machinery and TEs, in addition to general toxicological effects in the lung were assessed. CuO exhibited higher cell-damaging potential to the lung, while PEPs showed a greater ability to target the epigenome. Alterations in the methylation status of global DNA and TEs, and expression of TEs and DNA machinery in mouse lung were observed after exposure to CuO and PEPs. Additionally, epigenetic changes were detected in the peripheral blood after PEPs exposure. Altogether, CuO and PEPs can induce epigenetic alterations in a mouse experimental model, which in turn confirms that the recently developed in vitro epigenetic platform using macrophage and epithelial cell lines can be successfully utilized in the epigenetic screening of ENMs. 相似文献
37.
38.
39.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
40.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600